- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06260514
Study of APR-1051 in Patients With Advanced Solid Tumors
February 14, 2024 updated by: Aprea Therapeutics
A Phase 1, Open-Label, Multicenter, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APR-1051 in Patients With Advanced Solid Tumors
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
79
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Crystal L Miller, RN BSN
- Phone Number: 1-617-463-9385
- Email: crystal.miller@aprea.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of advanced/metastatic solid tumor
- Measurable or evaluable disease per RECIST version 1.1 (radiographic disease progression per PCWG3 criteria for patients with mCRPC)
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 or Karnofsky Performance Status (KPS) ≥ 70%
- Patients must have recovered to Grade 1 or baseline levels from toxicity or adverse events related to prior treatment for their cancer, excluding Grade ≤ 2 neuropathy, alopecia, or skin pigmentation
- Adequate bone marrow and organ function
- Women of child-bearing potential (WOCBP) or men of child-fathering potential must agree to use adequate contraception prior to study entry
Exclusion Criteria:
- Patient has had prior systemic anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy) within 3 weeks (6 weeks in cases of mitomycin C, nitrosourea, lomustine) or at least 5 half-lives (whichever is shorter, but no less than 2 weeks) prior to Day 1
- Prior radiation therapy at the target lesion unless there is evidence of disease progression. If patient has had prior radiation therapy for disease progression, see Exclusion Criterion 1 for allowed interval between radiotherapy and Day 1 and recovery of AEs
- Treatment with any investigational agent administered within 30 days or 5 half-lives, whichever is shorter, before the first dose of APR-1051
- Major surgery within 21 days prior to Day 1
- Concomitant treatment with other anti-cancer therapy, including chemotherapy, immunotherapy, biological therapy, radiation therapy (except palliative local radiation therapy), or other novel anti-cancer agents. Note: endocrine therapy for breast and prostate cancer is allowed along with agents to treat or prevent skeletal related events (zoledronic acid, pamidronate, denosumab)
- Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: APR-1051
3+3 Dose Escalation Design
|
WEE1 Inhibitor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-related adverse events
Time Frame: Day 1 to 28, each cycle is 28 days
|
|
Day 1 to 28, each cycle is 28 days
|
Recommended dose of APR-1051
Time Frame: Day 1 to 28, each cycle is 28 days
|
•Part 1 dose escalation: Recommended Phase 2 Dose (RP2D) of APR-1051 monotherapy [Time frame: Day 1 through to start of dose expansion phase].
The RP2D of will be determined based on review of safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy data
|
Day 1 to 28, each cycle is 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics: Cmax/Cmin of APR-1051
Time Frame: Day 1 to 112
|
Plasma concentration of APR-1051: maximum (Cmax), minimum (Cmin)
|
Day 1 to 112
|
Pharmacokinetics: Tmax of APR-1051
Time Frame: Day 1 to 112
|
Time to peak plasma concentration of APR-1051 (Tmax)
|
Day 1 to 112
|
Pharmacokinetics: AUC of APR-1051
Time Frame: Day 1 to 112
|
Area under plasma versus time curve (AUC) of APR-1051 max)
|
Day 1 to 112
|
Pharmacokinetics: t1/2 of APR-1051
Time Frame: Day 1 to 112
|
Half-life of APR-1051 (t1/2)
|
Day 1 to 112
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2028
Study Registration Dates
First Submitted
January 18, 2024
First Submitted That Met QC Criteria
February 14, 2024
First Posted (Estimated)
February 15, 2024
Study Record Updates
Last Update Posted (Estimated)
February 15, 2024
Last Update Submitted That Met QC Criteria
February 14, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APR-1051-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
GI Innovation, Inc.RecruitingAdvanced Solid Tumor | Metastatic Solid TumorKorea, Republic of, United States
-
Xenthera, Inc.Not yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on APR-1051
-
Stony Brook UniversityUnknownRectal AdenocarcinomaUnited States
-
Apyx MedicalCompleted
-
Apyx MedicalActive, not recruiting
-
Aprea TherapeuticsCompletedProstatic Neoplasms | Hematologic NeoplasmsSweden
-
Apyx MedicalRecruitingSkin Laxity | Tissue Breakdown | Collagen Degeneration | Collagen Shrinkage | Tissue DegenerationUnited States
-
Apyx MedicalActive, not recruiting
-
Apyx MedicalActive, not recruitingLabia Enlarged | Labium; HypertrophyUnited States
-
Apyx MedicalCompletedLax SkinUnited States
-
Peter MacCallum Cancer Centre, AustraliaTerminated
-
Apyx MedicalCompletedGynecomastiaUnited States